Straits Research Pvt Ltd
Global Rare Disease Diagnostics Market Size is Estimated to Reach USD 71.2 Billion by 2031, Growing at a CAGR of 8.62%: Straits Research
February 12, 2024 06:30 ET | Straits Research
New York, United States, Feb. 12, 2024 (GLOBE NEWSWIRE) -- This study examines the effects of uncommon diseases on a significant portion of the global population. There are over 7000 uncommon...
IMF_logo_RGB.png
Trace Genomics CEO & Co-Founder Poornima Parameswaran Elected to the International Myeloma Foundation’s Board of Directors
February 08, 2024 08:45 ET | International Myeloma Foundation
Trace Genomics CEO & Co-Founder Poornima Parameswaran Elected to the International Myeloma Foundation’s Board of Directors
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology to Participate in Upcoming Investor Conferences
February 06, 2024 07:01 ET | Olema Oncology
SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a biopharmaceutical company focused on the discovery, development, and...
arvinas_logoART_lg.jpg
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 06, 2024 06:45 ET | Arvinas Inc.
-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade the estrogen receptor (ER) protein -- NEW HAVEN, Conn. and NEW YORK,...
NOVARTIS logo.jpg
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
February 05, 2024 16:45 ET | Novartis Pharma AG
Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or...
arvinas_logoART_lg.jpg
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
February 01, 2024 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
RM Primary Logo - Humble.png
Revolution Medicines to Participate in Upcoming Investor Conferences
February 01, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
PRISM MarketView Marks World Cancer Day
PRISM MarketView Marks World Cancer Day
February 01, 2024 10:45 ET | PRISM MarketView
PRISM MarketView Marks World Cancer Day
finacialnews-logo-final-01 (2).png
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024 09:15 ET | FN Media Group LLC
PALM BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports show that the Multiple myeloma Diagnostic market will continue to grow in the next several years....
ITM_Logo_Claim_RGB_high-res.png
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
January 30, 2024 07:00 ET | ITM Isotope Technologies Munich SE
GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9),...